NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/07/2025
Back to search
Official data from USPTO
ELLIPSES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
10/08/2025
Trademark type
Word
Nice classes
5, 42
Filing date
08/17/2021
Registration date
10/07/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/07/2025
Last transaction
10/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
MOSCATI,JUSTIN RONALD
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Ellipses Pharma Ltd
Representatives
John C. Cain Munck Wilson Mandala, LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of cancer; veterinary preparations for the treatment of cancer; dietetic preparations for medical purposes; dietetic foods for use in clinical nutrition; food supplements; nutraceuticals for therapeutic and medical purposes; medicated food supplements; biological preparations for the treatment of cancer; anti-cancer preparations; anti-cancer drugs being preparations; compounds for treating cancer being pharmaceutical preparations; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; all of the aforesaid for use in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Class 42
Medical and pharmacological research services; biological research; clinical research in the field of oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofsurgery in relation to cancer; medical research; providing an online network environment for research and development for drug and pharmaceutical development; providing an online network environment for the designdevelopment and testing of drugs and pharmaceuticals; Providing scientific and technological services and researchanalysisdesign relating thereto; designdevelopment and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; laboratory research into new drugs and pharmaceutical products; pharmaceutical drug development services; research relating into medicines; consultancy services relating to scientific and medical research; expert advice relating to drug developmentbeing consulting services in the field of pharmaceutical research; laboratory analysis in the field of pharmaceutical research; computer hardware and software design and development in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; computer network services in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; software hosting services in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; software as a service in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; Information Technology (IT) consultancyadvisory and information services relating to a network of medical research professionals; scientific advisory services; scientific research projects and studies being scientific research and development; conducting clinical trials being scientific and medical research for others; scientific and medical clinical research for others; clinical research for cancer treatments and pharmaceuticals; providing an online network environment for clinical trials; conducting and collating a research network for treatmentcure and prevention of cancer being medical and scientific research; development of measuring and testing methods being research and development in the field of pharmaceuticals; quality control of services; evaluation of drug development services; industrial testingindustrial design services; pharmaceutical product evaluation; testing of chemicals
Publications
History of USPTO decisions and trademark events.
32 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/03/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/19/2025
PUBO
PUBLISHED FOR OPPOSITION
08/19/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/13/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/10/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/14/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/14/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/14/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/14/2025
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
01/06/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/21/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/21/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/21/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/21/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
05/08/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/07/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
12/29/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
06/08/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/25/2022
GNSL
LETTER OF SUSPENSION E-MAILED
11/25/2022
CNSL
SUSPENSION LETTER WRITTEN
11/25/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/24/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/23/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/23/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/23/2022
GNRT
NON-FINAL ACTION E-MAILED
05/23/2022
CNRT
NON-FINAL ACTION WRITTEN
05/23/2022
DOCK
ASSIGNED TO EXAMINER
05/18/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/05/2021
NWAP
NEW APPLICATION ENTERED
08/20/2021
Continuous trademark protection
Get notified about every new filing that threatens ELLIPSES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.